ScholarIQanswers from OpenAlex & ORCID
Geoffrey I. Shapiro
ResearcherPublications, citations & collaboration network
Geoffrey I. Shapiro is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Geoffrey I. Shapiro have?
ScholarIQindexed works
Geoffrey I. Shapiro has 2,057 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Geoffrey I. Shapiro have?
ScholarIQcitation count
Geoffrey I. Shapiro has 58,369 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Geoffrey I. Shapiro?
ScholarIQh-index
Geoffrey I. Shapiro has an h-index of 116 in OpenAlex.
What is the i10-index of Geoffrey I. Shapiro?
ScholarIQi10-index
Geoffrey I. Shapiro has an i10-index of 395 in OpenAlex.
What is the ORCID of Geoffrey I. Shapiro?
ScholarIQorcid
The ORCID for Geoffrey I. Shapiro is on the source record.
What is the OpenAlex record for Geoffrey I. Shapiro?
ScholarIQopenalex
The OpenAlex for Geoffrey I. Shapiro is on the source record.
What are the most-cited papers on Geoffrey I. Shapiro?
ScholarIQmost cited works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate
KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, Gregory A. Durm, Geoffrey I. Shapiro, Gerald S. Falchook, Timothy Price, Adrian G. Sacher, Crystal S. Denlinger, Yung‐Jue Bang, Grace K. Dy, John C. Krauss, Yasutoshi Kuboki, James Kuo, Andrew L. Coveler, Keunchil Park, Tae Won Kim, Fabrice Barlési, Pamela N. Münster, Suresh S. Ramalingam, Timothy F. Burns, Funda Meric‐Bernstam, Haby Henary, Jude Ngang, Gataree Ngarmchamnanrith, June Myung Kim, Brett E. Houk, Jude Canon, J. Russell Lipford, Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay, Shohei Koyama, Julián Carretero, Abigail Altabef, Jeremy H. Tchaicha, Camilla L. Christensen, Oliver R. Mikse, Andrew D. Cherniack, Ellen M. Beauchamp, Trevor J. Pugh, Matthew D. Wilkerson, Peter E. Fecci, Mohit Butaney, Jacob B. Reibel, Margaret Soucheray, Travis J. Cohoon, Pasi A. Jänne, Matthew Meyerson, D. Neil Hayes, Geoffrey I. Shapiro, Takeshi Shimamura, Lynette M. Sholl, Scott J. Rodig, Gordon J. Freeman, Peter S. Hammerman, Glenn Dranoff, Kwok‐Kin Wong